Oncorus, Inc. (NASDAQ:ONCR – Get Rating) major shareholder James E. Flynn sold 99,718 shares of the business's stock in a transaction that occurred on Monday, December 19th. The shares were sold at an average price of $0.29, for a total transaction of $28,918.22. Following the completion of the sale, the insider now directly owns 332,725 shares in the company, valued at $96,490.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
Oncorus Stock Down 8.3 %
ONCR traded down $0.03 during trading hours on Wednesday, hitting $0.28. 86,612 shares of the company's stock were exchanged, compared to its average volume of 130,208. Oncorus, Inc. has a 12-month low of $0.27 and a 12-month high of $5.76. The firm has a 50 day moving average of $0.57 and a 200 day moving average of $1.04. The firm has a market cap of $7.27 million, a P/E ratio of -0.10 and a beta of 2.24. The company has a current ratio of 4.97, a quick ratio of 4.97 and a debt-to-equity ratio of 0.24.
Get Oncorus alerts:Oncorus (NASDAQ:ONCR – Get Rating) last posted its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.01. Analysts predict that Oncorus, Inc. will post -2.69 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in ONCR. Millennium Management LLC acquired a new position in Oncorus during the 2nd quarter worth approximately $476,000. Renaissance Technologies LLC boosted its holdings in shares of Oncorus by 1,144.9% in the 1st quarter. Renaissance Technologies LLC now owns 175,532 shares of the company's stock valued at $312,000 after buying an additional 161,432 shares in the last quarter. Private Advisor Group LLC acquired a new position in shares of Oncorus in the 1st quarter valued at $112,000. Bank of New York Mellon Corp boosted its holdings in shares of Oncorus by 106.6% in the 1st quarter. Bank of New York Mellon Corp now owns 122,047 shares of the company's stock valued at $218,000 after buying an additional 62,985 shares in the last quarter. Finally, Sawtooth Solutions LLC acquired a new position in shares of Oncorus in the 1st quarter valued at $112,000. Institutional investors and hedge funds own 65.89% of the company's stock.Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the stock. Piper Sandler downgraded shares of Oncorus from an "overweight" rating to a "neutral" rating and reduced their price target for the company from $6.00 to $2.00 in a research note on Wednesday, November 30th. Chardan Capital downgraded shares of Oncorus from a "buy" rating to a "neutral" rating in a research note on Wednesday, November 30th. Finally, HC Wainwright downgraded shares of Oncorus from a "buy" rating to a "neutral" rating in a research note on Tuesday, December 6th.
Oncorus Company Profile
(Get Rating)
Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.
Read More
- Get a free copy of the StockNews.com research report on Oncorus (ONCR)
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
- Will AMC's Troubles Affect Its Landlord, EPR Properties?
Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.